This article is for research investigators and institutional administrators. It does not constitute legal or regulatory advice. Verify all requirements with your institution's Office of Research and the NIH program officer for your specific application.
Deadline Alert
NIH R01 standard due date for new applications: June 5, 2026. Clinical trial R01s require additional lead time — IND/IDE status, IRB approval plan, and DSMB arrangements must all be addressed in the application. Start Human Subjects sections now.
Summary
The NIH R01 Research Project Grant is the primary funding mechanism for investigator-initiated clinical trials at NIH — supporting Phase I through Phase III studies and observational research involving human participants. Clinical trial R01s follow the same June 5, 2026 standard due date but have substantially more complex application requirements than basic or translational science R01s. The clinical trial-specific sections — Human Subjects, Inclusion Enrollment Report, Data Safety Monitoring Plan, and IND/IDE status — require weeks of preparation and institutional coordination.
Clinical Trial R01 vs. Basic Science R01
- Clinical Trial Required (CTR) designation: Applications that include an NIH-defined clinical trial must use a CTR-specific FOA — submitting to a non-CTR FOA will result in rejection without review
- Additional required sections: Human Subjects Research, Inclusion of Women, Minorities, and Children sections, Data Safety Monitoring Plan, Single IRB designation (for multi-site trials), Dissemination Plan
- IND/IDE requirement: If the trial uses an investigational drug or device, IND (Investigational New Drug) or IDE (Investigational Device Exemption) status must be addressed — applicants must either have an IND/IDE, describe a plan to obtain one, or explain why one is not required
- ClinicalTrials.gov registration: All NIH-funded clinical trials must be registered on ClinicalTrials.gov before initiation — the registration plan should be described in the application
What Reviewers Evaluate in Clinical Trial R01s
- Trial design rigor: Is the design (randomized, blinded, placebo-controlled, adaptive) appropriate for the research question? Is the control arm justified? Are endpoints clinically meaningful and measurable?
- Power and sample size: Is the power calculation well-justified? Does the accrual plan demonstrate that the required sample size is achievable within the project period?
- Recruitment feasibility: Can the team actually enroll the required number of participants? Reviewers look for documented access to patient populations, site experience, and contingency plans for slow accrual.
- Safety monitoring: Is the DSMB (Data Safety Monitoring Board) plan appropriate? For Phase I/II trials, what stopping rules are in place?
- Team qualifications: Does the PI have clinical trial experience? Is there a biostatistician? Is there a clinical research coordinator infrastructure?
How to Apply — Step by Step
- Step 1 — Confirm "Clinical Trial Required" or "Not Allowed" status: Determine whether your study is an NIH-defined clinical trial. NIH's Clinical Trial Decision Tool (available at grants.nih.gov) helps determine this — the answer affects which FOAs you can use.
- Step 2 — Find the correct FOA: Search for R01 FOAs using NIH Guide or the Grants.gov search. Filter for "Clinical Trial Required" FOAs. Contact the IC Program Officer to confirm fit before preparing a full application.
- Step 3 — Begin Human Subjects sections: The Protection of Human Subjects section for a clinical trial is extensive — IRB approval status, recruitment and consent procedures, potential risks and benefits, and special populations must all be documented. Allow 3–4 weeks for this section alone.
- Step 4 — Address IND/IDE status: Contact your institution's regulatory affairs office to confirm IND/IDE status. If a new IND is needed, initiate FDA contact immediately — FDA pre-IND meetings can take 2–3 months to schedule.
- Step 5 — Prepare DSMB charter and membership plan: A Data Safety Monitoring Board is required for most Phase II and all Phase III trials. Identify potential DSMB members and describe the monitoring plan, meeting frequency, and stopping rules.
- Step 6 — Submit via Grants.gov: Deadline is June 5, 2026. Allow 5–7 business days for institutional sign-off. Clinical trial applications are large — budget ample time for file uploads and last-minute corrections.
Key Deadlines
- June 5, 2026 — New R01 standard due date (Clinical Trial Required)
- July 5, 2026 — A1 resubmission due date
- ~October 2026 — Study Section review meetings for June submissions
- ~December 2026 — Summary Statements released for June submissions
- October 5, 2026 — Next new R01 standard due date